Molecular Formula | C28H27F4N7O3S |
Molar Mass | 617.6176928 |
Solubility | DMSO: 10.25 mg/mL |
Storage Condition | -20℃ |
In vitro study | In HCT116 colon cancer cells, LY2584702 inhibit modulation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μm. LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus. In HCT116 colon cancer cells, LY2584702 inhibited the phosphorylation of S6 ribosomal protein (pS6) with an IC50 of 0.1-0.24 μm. LY2584702 has a significant synergistic effect when combined with the EGFR inhibitor erlotinib or the mTOR inhibitor everolimus. |
In vivo study | LY2584702 (12.5 mg/kg BID, potentially significant anti-tumor in blood U87MG gliobastoma and HCT116. LY2584702 (12.5 mg/kg BID) showed significant anti-tumor activity in U87MG malignant glioma and HCT116 colon cancer xenograft model. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.619 ml | 8.096 ml | 16.191 ml |
5 mM | 0.324 ml | 1.619 ml | 3.238 ml |
10 mM | 0.162 ml | 0.81 ml | 1.619 ml |
5 mM | 0.032 ml | 0.162 ml | 0.324 ml |